Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance

Table 1

Blood glucose level, glucose infusion rate (GIR), and endogenous glucose production (EGP) of RO5126766-treated db/db mice in the hyperinsulinemic-euglycemic clamp test.

	Control	RO5126766	Pioglitazone
		(2 mg in 1 kg CE-2)	(200 mg in 1 kg CE-2)
	10	10	5
Blood glucose (mg⋅dL^−1) (4 h fasted)	272.9 ± 30.6	141.2 ± 12.9	104.6 ± 12.4
Blood glucose (mg⋅dL^−1)	121.3 ± 8.7	109.5 ± 2.7	107.9 ± 3.0
GIR (mg⋅kg^−1⋅min^−1)	9.5 ± 2.1	26.8 ± 2.7	29.7 ± 5.7
EGP (mg⋅kg^−1⋅min^−1)	16.8 ± 3.7	6.8 ± 2.3	−0.9 ± 3.0
Plasma insulin (ng⋅mL^−1)	43.7 ± 3.5	50.4 ± 6.4	41.6 ± 8.8

Data are expressed as mean ± SEM.
Mean values of last 60 min on clamp.
, , and versus control by parametric Dunnett’s multiple comparison test.
.